HER2-CD3-hFc mRNA-LNP

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameHER2-CD3-hFc mRNA-LNP
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > mRNABiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 stimulantsReceptor protein-tyrosine kinase erbB-2 binders
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesForevertek Biotechnology Co LtdProMab Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesProMab Biotechnologies IncForevertek Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A